Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Karin Jordan



Department of Haematology and Oncology
University Hospital Heidelberg

Professor Karin Jordan graduated from Martin Luther University of Halle-Wittenberg, Germany. Following a number of posts at the University Hospital Halle and Bernward Hospital, Hildesheim, she was appointed as a specialist in Internal Medicine and Haematology and Oncology at the University of Halle-Wittenberg.

Since 2017 she is the leading senior physician of the Department of Haematology and Oncology at the University Hospital in Heidelberg, Germany. She was the vice executive director of the ethics committee at the University of Halle from 2009-2017. 

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel since 2009, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Association of Supportive Care in Oncology (AGSMO). 

Professor Jordan is a member of the ESMO Council and Chair of the Educational Committee and a member of the Leadership Generation Task Force. She is a Subject Editor for the Supportive Care section of the ESMO Clinical Practice Guidelines and also a member of the Guidelines Steering Committee. Since 2014, she serves as an Associate Editor of Annals of Oncology and since 2018 as a member of the Editorial Board of ESMO Open.  She was previously a member of the ESMO Young Oncologist Committee and the ESMO Faculty Coordinator for Supportive and Palliative Care.   Since 2013, she is the coordinator of the S3 Guidelines on Supportive Care within the Oncology Guideline Program of the German Cancer Society

Professor Jordan has authored and co-authored more than 200 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

Last update: February 2021

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.